Research programme: recombinant fusion protein therapeutics - Mannin
Latest Information Update: 27 Dec 2022
At a glance
- Originator Mannin
- Class Antiglaucomas; Antivirals; Recombinant fusion proteins
- Mechanism of Action TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Kidney disorders; Open-angle glaucoma
Most Recent Events
- 27 Dec 2022 Preclinical trials in COVID-2019 infections in Germany (unspecified route) before December 2022 (Mannin website, December 2022)
- 27 Dec 2022 Preclinical trials in Kidney disorders in Germany (unspecified route) before December 2022 (Mannin website, December 2022)
- 27 Dec 2022 Preclinical trials in Open-angle glaucoma in Germany (unspecified route) before December 2022 (Mannin website, December 2022)